World News: 21:05 GMT Wednesday 15th May 2019. [Bellicum Pharmaceuticals, Inc. via Globe Newswire via SPi World News]
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that its abstract for BPX-601 has been accepted for poster presentation at the . The meeting is being held May 31 – June 4, 2019 in Chicago.
Details of the poster presentation are as follows:
BPX-601, the company’s first GoCAR-T product candidate, incorporates iMC, Bellicum’s inducible co-activation domain. iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for solid tumors expressing prostate stem cell antigen (PSCA), including pancreatic, gastric, and prostate cancers.
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. More information can be found at .
Source: Bellicum Pharmaceuticals
Media: Jim Heins Senior Vice President Westwicke PR 203-682-8251
Globe Newswire: 21:05 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.